REG - Nuformix PLC - Result of General Meeting

NuformixAnnouncement

31/01/2022 11:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220131:nRSe1561Aa&default-theme=true

RNS Number : 1561A  Nuformix PLC  31 January 2022

 

Nuformix plc

("Nuformix" or the "Company")

 

Result of General Meeting

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, confirms that,
further to the announcement made in connection with the Subscription to raise
£1.65 million with Lanstead Capital Investors L.P., at the General Meeting
held earlier today all Resolutions were passed by way of a poll, the full
results of which are given below:

 

    Resolution                                                                   Ordinary/ Special  For                   Against              Total votes cast
                                                                                                    No. of votes  %       No. of votes  %
 1  THAT, in addition to existing authorities, the directors are authorised to   Ordinary           81,448,911    95.22%  4,093,030     4.78%  85,541,941
    exercise all powers of the Company to allot new ordinary shares

 2  THAT, upon the passing of Resolution 1, the Directors be empowered to allot  Special            81,438,942    95.19%  4,116,235     4.81%  85,555,177
    new ordinary shares for cash on a non-pre-emptive basis.

Accordingly, the Company now has sufficient authorities in place to allot the
Second Subscription Shares and the Second Value Payment Shares. The Second
Subscription remains conditional on there being no requirement for the Company
to publish a prospectus in connection with the Second Subscription. It is
expected that the Second Subscription Shares and the Second Value Payment
Shares will be issued in April 2022 and at that point application will be made
to the London Stock Exchange and the Financial Conduct Authority for
Admission.

 

Notes:

1.  Any proxy arrangement which gave discretion to the Chairman has been
included in the "for" totals.

2.  A "Vote withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against" any
resolution.

3.  The number of shares in issue at close of business on 28 January 2022 was
615,609,368. The Company does not hold any shares in treasury.

 

Unless otherwise defined, all capitalised terms used but not defined in this
announcement shall have the meaning given to them in the Circular dated 14
January 2022, a copy of which is available to view on the Company's website
(www.nuformix.com (http://www.nuformix.com) ).

 

Enquiries:

 

 Nuformix plc                                        via Walbrook
 Dr Alastair Riddell, Executive Chairman

 Allenby Capital Limited                             +44 (0) 20 3328 5656
 Nick Athanas / George Payne (Corporate Finance)
 Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

 Walbrook PR       nuformix@walbrookpr.com or +44 (0)20 7933 8780
 Anna Dunphy / Phillip Marriage      Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

 

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical and Phase
I-ready assets with potential for significant value and early licensing
opportunities.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMGZGFMMMMGZZM